Cargando…

Donor T cells for CAR T cell therapy

Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Tiffany C. Y., Xu, Ning, Nordon, Robert, Haber, Michelle, Micklethwaite, Kenneth, Dolnikov, Alla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973942/ https://www.ncbi.nlm.nih.gov/pubmed/35365224 http://dx.doi.org/10.1186/s40364-022-00359-3

Ejemplares similares

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

Characterizing piggyBat—a transposase for genetic modification of T cells
por: Sutrave, Gaurav, et al.
Publicado: (2022)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

The expansion of targetable biomarkers for CAR T cell therapy
por: Townsend, Michelle H., et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
por: Bishop, David C., et al.
Publicado: (2020)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

CAR-T cell therapy in ovarian cancer: from the bench to the bedside
por: Zhu, Xinxin, et al.
Publicado: (2017)

CAR-T cell therapy: current limitations and potential strategies
por: Sterner, Robert C., et al.
Publicado: (2021)

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
por: Bulliard, Yannick, et al.
Publicado: (2023)

CAR-T Cell Therapy: From the Shop to Cancer Therapy
por: Uscanga-Palomeque, Ashanti Concepción, et al.
Publicado: (2023)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Practical issues in CAR T-cell therapy
por: Byun, Ja Min
Publicado: (2023)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
por: Zhang, Xi-Wen, et al.
Publicado: (2023)

Emerging Novel Combined CAR-T Cell Therapies
por: Nguyen, Anh, et al.
Publicado: (2022)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

Podoplanin as an Attractive Target of CAR T Cell Therapy
por: Waseda, Masazumi, et al.
Publicado: (2020)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

CAR T Cell Therapy: A Versatile Living Drug
por: De Marco, Rodrigo C., et al.
Publicado: (2023)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
por: Huang, Shengkang, et al.
Publicado: (2023)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uvikj4blh6fq4f7qi3clcn4kr3